Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 285-291

  Delpech, Y ^a,b   Coutant, C ^c   Hsu, L ^a   Barranger, E ^b   Iwamoto, T ^a   Barcenas, C H ^a   Hortobagyi, G N ^a   Rouzier, R ^d   Esteva, F J ^a   Pusztai, L ^a,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Georges Francois Leclerc Cancer Center   (France)

^d HÔPITAL TENON   (France)

^e YALE CANCER CENTER   (United States)

Author keywords

Breast cancer; Clinical response; Lobular carcinoma; Margins; Neoadjuvant chemotherapy; Pathological complete response

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873567924     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.557     Document Type: Article

References (34)

1. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict cncotype DX recurrence scores in subsets of ER positive patients: Who does not always need testing? Breast Cancer Res Treat 131(2): 413-424.
2. Arpino G, BardoüVJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res 6(3): R149-R156.
3. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM (2006) Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244(3): 464-470.
4. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I (2009) Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 16(6): 1606-1611.
5. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptorpositive breast cancer: The Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial. Cancer 106(10): 2095-2103. (Pubitemid 43673229)
6. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29(4): 361-367. (Pubitemid 36675693)
7. Cristofanilli M, Gonzalez-Angulo A, Sneige N, KaüSW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN (2005) Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1): 41-48. (Pubitemid 41702621)
8. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12(11): 1527-1532. (Pubitemid 34065880)
9. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29(17): 2342-2349.
10. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr. AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8): 2672-2685. (Pubitemid 28363030)
11. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36(1): 1-85.
12. Huober J, von Minckwitz G, Denkert C, Tesch H,Weiss E, Zahm DM, BelaüA, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 124(1): 133-140.
13. Katz A, Saad ED, Porter P, Pusztai L (2007) Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8(1): 55-62. (Pubitemid 44943091)
14. Katz MH (2003) Multivariable analysis: A primer for readers of medical research. Ann Intern Med 138(8): 644-650. (Pubitemid 38124656)
15. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22): 5161-5167.
16. Lips EH, Mukhtar RA, YaüC, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E (2012) Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 136(1): 35-43.
17. MathieüMC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40(3): 342-351. (Pubitemid 38121270)
18. Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R (2008) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: A phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 112(1): 203-213.
19. Molland JG, Donnellan M, JanüNC, Carmalt HL, Kennedy CW, Gillett DJ (2004) Infiltrating lobular carcinoma-a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 13(5): 389-396. (Pubitemid 39549788)
20. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ (2010) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21(4): 717-722.
21. Mustacchi G, Mansutti M, Sacco C, Barni S, Farris A, Cazzaniga M, Cozzi M, Dellach C (2009) Neo-adjuvant exemestane in elderly patients with breast cancer: A phase II, multicentre, open-label, Italian study. Ann Oncol 20(4): 655-659.
22. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23): 2020-2028.
23. Purushotham A, Pinder S, Cariati M, Harries M, Goldhirsch A (2010) Neoadjuvant chemotherapy: Not the best option in estrogen receptorpositive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 28(22): 3552-3554.
24. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, MathieüMC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23(33): 8331-8339.
25. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110(2): 244-254. (Pubitemid 47121883)
26. Soucy G, Belanger J, Leblanc G, Sideris L, Drolet P, Mitchell A, Leclerc YE, Dufresne MP, Beaudet J, Dube P (2008) Surgical margins in breast-conservation operations for invasive carcinoma: Does neoadjuvant chemotherapy have an impact? J Am Coll Surg 206(3): 1116-1121.
27. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17(9): 2411-2418.
28. Sullivan PS, Apple SK (2009) Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J 15(2): 146-154.
29. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P, Rouesse J (2006) Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 17(8): 1228-1233. (Pubitemid 44288213)
30. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15): 1796-1804.
31. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I (2009) Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg 198(3): 387-391.
32. Waljee JF, HüES, Newman LA, Alderman AK (2008) Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol 15(5): 1297-1303.
33. Wellings SR, Jensen HM, Marcum RG (1975) An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55(2): 231-273.
34. World Health Organisation (1982) The World Health Organization Histological Typing of Breast Tumours-Second Edition. The World Organization. Am J Clin Pathol 78(6): 806-816.